Axonics, Inc. Stock

Equities

AXNX

US05465P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-28 pm EDT 5-day change 1st Jan Change
67.13 USD -0.13% Intraday chart for Axonics, Inc. -0.68% +7.87%
Sales 2024 * 447M Sales 2025 * 537M Capitalization 3.43B
Net income 2024 * -4M Net income 2025 * 36M EV / Sales 2024 * 6.94 x
Net cash position 2024 * 329M Net cash position 2025 * 370M EV / Sales 2025 * 5.7 x
P/E ratio 2024 *
-695 x
P/E ratio 2025 *
95.9 x
Employees 797
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.16%
1 week-0.47%
Current month+0.98%
1 month+0.79%
3 months-1.60%
6 months+16.64%
Current year+8.02%
More quotes
1 week
66.98
Extreme 66.975
67.73
1 month
66.32
Extreme 66.32
67.91
Current year
55.09
Extreme 55.09
69.68
1 year
47.59
Extreme 47.59
69.68
3 years
38.41
Extreme 38.41
79.92
5 years
15.25
Extreme 15.25
79.92
10 years
11.95
Extreme 11.95
79.92
More quotes
Managers TitleAgeSince
Founder 51 12-12-31
Founder 65 13-09-30
Director of Finance/CFO 39 13-12-31
Members of the board TitleAgeSince
Chairman 53 19-02-26
Director/Board Member 72 19-04-07
Founder 65 13-09-30
More insiders
Date Price Change Volume
24-05-28 67.13 -0.13% 299 937
24-05-24 67.22 -0.16% 291,184
24-05-23 67.33 -0.44% 559,373
24-05-22 67.63 +0.06% 505,077
24-05-21 67.59 +0.07% 253,786

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
67.22 USD
Average target price
71.8 USD
Spread / Average Target
+6.81%
Consensus